司他夫定衍生物的合成及抗肿瘤活性评价

目的设计合成一系列司他夫定类衍生物,并评价其抗肿瘤活性。方法以司他夫定为原料,经磺酸酯化后与叠氮化钠反应生成5'-叠氮基司他夫定,再通过Huisgen 1,3-偶极环加成反应得到目标化合物。采用MTT法分别以人肝癌细胞(BEL-7402)、人胃癌细胞(BGC-823)、肺癌细胞(A549)为测试细胞株对目标化合物进行体外抗肿瘤活性评价。结果与结论合成了14个5'-脱氧司他夫定衍生物,目标化合物的结构经核磁共振氢谱和碳谱确证。其中化合物4k对人肝癌细胞(BEL-7402)、人胃癌细胞(BGC-823)、肺癌细胞(A549)具有中等的抑制作用。     

3,4-二氢-4-芳基香豆素类化合物的合成及其生物活性研究

目的 设计合成一系列3,4-二氢4-芳基香豆素类化合物,并评价其抗氧化、抗肿瘤活性.方法 以取代苯甲醛为原料,经缩合及Ponndorf反应制得目标化合物.采用DPPH法测定目标化合物的抗氧化活性;采用MTT法以胃癌细胞BGC-823为测试细胞株对目标化合物进行体外抗肿瘤活性评价.结果 与结论合成了10个新的3,4-二氢...     

1-苯胺基-5H-哒嗪并[4,5-b]吲哚类化合物的合成及体外抗肿瘤活性

目的设计并合成1-苯胺基-5H-哒嗪并[4,5-b]吲哚类化合物,评价其体外抗肿瘤活性。方法以5-乙酰氧基-6-溴-2-溴甲基-1-环丙基-1H-吲哚-3-羧酸乙酯为起始原料,经8～9步反应合成目标化合物;采用MTT法,测定了目标化合物对肿瘤细胞株Bel-7402和HT-1080的抑制活性。结果与结论合成了12个新化合物,其结构经1H-NMR和MS确证;多个化合物显示出良好的抗肿瘤活性,化合物10a和10d活性突出,对肿瘤细胞株Bel-7402和HT-1080的抑制活性分别是阳性对照药gefitinib的4倍和5倍,值得进一步研究。     

2-（E）-（3-甲氧基-4-环戊氧基苯基亚甲基）环戊酮衍生物的合成及抗肿瘤活性

目的设计并合成一系列2-（E）-（3-甲氧基-4-环戊氧基苯基亚甲基）环戊酮衍生物，并对其体外抗肿瘤活性进行筛选。方法合成目标化合物并用人肝癌细胞（Bel-7402）和人口腔癌细胞（KB）对化合物的体外抗肿瘤活性进行筛选。结果合成了5个目标化合物，其中3个未见文献报道。化合物的结构经IR、^1H NMR、MS和元素分析确证。初筛结果显示化合物5具有较高的活性，对Bel-7402和KB细胞的IC50值分别为1．62gmol·L^-1和8．04gmol·L^-1,但低于对照药5-氟脲嘧啶。结论2-（E）-（3-甲氧基-4-环戊氧基苯基亚甲基）环戊酮Mannich碱衍生物具有一定抗肿瘤活性。     

取代苯基亚甲基环戊酮衍生物的设计、合成与抗肿瘤活性

目的 设计并合成一系列取代苯基亚甲基环戊酮衍生物,对它们的体外抗肿瘤活性进行初步筛选并探讨其构效关系。方法 使用化学方法对目标化合物进行合成,采用MTT法测定目标化合物的体外抗肿瘤活性,利用CoMFA法讨论构效关系。结果与结论 合成了23个目标化合物,其中22个未见文献报道,目标化合物的结构经元素分析、¹H-NMR和MS谱确认。体外抗肿瘤活性初筛结果显示,化合物Ⅰa和Ⅰb对Bel-7402、HCT-8、A-549 肿瘤细胞均表现出较高的细胞毒性,化合物Ⅱg对Bel-7402和HCT-8呈现选择性抑制,但对A-549无抑制作用,化合物 Ⅲa~Ⅲf 对3种肿瘤细胞均无明显抑制作用。CoMFA 结果显示,5位芳基胺甲基结构中,胺基的对位含有空间位阻较小和吸电子基团时将有助于提高化合物的活性,而胺基的邻位和间位连有空间位阻较大和供电子基团将会增强化合物的活性。     

20(S)-7-烷(芳)酰基喜树碱的合成

20(S)-喜树碱(2)在过硫酸铵和硫酸亚铁作用下,以75%硫酸为溶剂,分别与戊醛和糠醛进行Minisci反应,制得20(S)-7-戊酰基喜树碱(1a)和20(S)-7-(2-糠酰基)喜树碱(1b),收率分别为81.3%和56.0%.对1a、1b和2用SRB法进行了人白血病(HL-60)、人胃癌细胞(BGC-823)、人肝癌细胞(Bel-7402)和人鼻咽癌细胞(KB)的体外抗肿瘤活性试验.结果显示,1a、1b对HL-60、BGC-823的抑制作用较2强;对Bel-7402和KB的抑制作用较2弱.     

吡唑并[1，5-α]嘧啶类化合物的合成及其抗肿瘤活性

目的设计合成新的吡唑并[1,5-a]嘧啶类化合物,并评价其抗肿瘤活性。方法根据吡唑并[1,5-a]嘧啶类抗肿瘤药物的基本结构设计了一系列5-胺甲基-7-苯胺基吡唑并[1,5-a]嘧啶类化合物,并以丙二腈和原甲酸三乙酯为起始原料,经5步反应得到目标产物。采用MTT法,以顺铂为阳性对照药,以Bel-7402和HT-1080为测试细胞株对目标化合物的抗肿瘤活性进行评价。结果与结论合成了11个未见文献报道的化合物,结构经质谱和核磁共振氢谱确证。化合物6显示出很好的抗肿瘤活性。     

吡唑并[1,5-a]嘧啶类化合物的合成及其抗肿瘤活性

目的 设计合成新的吡唑并[1,5-a]嘧啶类化合物,并评价其抗肿瘤活性.方法 根据吡唑并[1,5-a]嘧啶类抗肿瘤药物的基本结构设计了一系列5-胺甲基-7-苯胺基吡唑并[1,5-a]嘧啶类化合物,并以丙二腈和原甲酸三乙酯为起始原料,经5步反应得到目标产物.采用MTT法,以顺铂为阳性对照药,以Bel-7402和HT-1080为测试细胞株对目标化合物的抗肿瘤活性进行评价.结果与结论 合成了11个未见文献报道的化合物,结构经质谱和核磁共振氢谱确证.化合物6显示出很好的抗肿瘤活性.     

4-芳氨基-6-溴喹唑啉类化合物的合成及抗肿瘤活性的初步研究

目的 设计合成新的4-芳氨基-6-溴喹唑啉类化合物,并评价其抗肿瘤活性。 方法 以4-氯-6-溴喹唑啉和含有不同取代基的(E)-氨基二苯乙烯或4-[2-（2-呋喃基）]乙烯基苯胺为原料,经过亲核取代反应合成了5种目标化合物。采用MTT法,以人低分化胃癌细胞（BGC-823）和人肺癌细胞（A549）为受试细胞株对目标化合物进行体外抗肿瘤活性评价。 结果与结论 所得化合物的结构利用IR、1HNMR、13CNMR和元素分析进行了确认。5种化合物对BGC-823和A549两种细胞模型的体外抗肿瘤活性测试结果表明,大部分化合物具有较好的抗肿瘤活性。     

1-苯氨基-5H-哒嗪并[4,5-b]吲哚类化合物的设计、合成及体外抗肿瘤活性

目的设计并合成1-苯氨基-5H-哒嗪并[4,5-b]吲哚类化合物,评价其抗肿瘤活性。方法以5-乙酰氧基-6-溴-2-溴甲基-1-环丙基-1H-吲哚-3-羧酸乙酯为起始原料,经多步反应合成目标化合物。采用MTT法,gefitinib为阳性对照药,以Bel-7402和HT-1080为测试细胞株对目标化合物抗肿瘤活性进行进行检测。结果合成了8个未见文献报道的新化合物,其结构经1H-NMR和MS确证。体外活性实验表明：多种化合物显示良好的抗肿瘤活性,其中化合物10f对Bel-7402和HT-1080肿瘤细胞株的抑制作用分别是阳性对照药gefitinib的6倍和7倍。结论1-苯氨基的苯环上的取代基和1-苯氨基-5H-哒嗪并[4,5-b]吲哚的8位引入的3-[[5-（脂肪（环）胺甲基）呋喃-2-基]甲硫基]丙氧基中脂肪（环）氨的种类均显著影响化合物的活性。     

4-酰基-5-吡唑酮的二烃基锡配合物的合成、表征及其抗癌活性研究

目的　设计合成一系列新型有机锡化合物,通过药理筛选寻找具有抗肿瘤活性的药物并探讨其构效关系。方法　以4-酰基-5-吡唑酮为配体合成有机锡化合物,用元素分析、红外光谱、 ¹H,¹³C,¹¹⁹Sn NMR等方法对得到的化合物作结构表征并利用几种药理模型进行体外抗癌活性筛选。结果　合成了一系列R₂SnL₂ 型有机锡新配合物并确定其结构。结论　药理筛选结果表明,多个化合物(3～6,9～11)对HL-60, HCT-8, Bel-7402,BGC-823和KB癌细胞有效,显示了较强的抗癌活性。     

Design, synthesis, and biologic evaluation of some novel N-arylpyrazole derivatives as cytotoxic agents

A novel series of N-arylpyrazole derivatives (5a–5d, 7a–7c) has been designed and synthesized via aromatic substitution reaction of N-nonsubstituted pyrazoles with 4-fluoronitrobenzene in the presence of base. The structures of these compounds were established on the basis of elemental (C, H, and N) and spectral analysis (¹H NMR, ¹³C NMR, HRMS, and FT-IR). All the compounds were tested for their cytotoxic activity in vitro against four human tumor cell lines: carcinoma (Bel-7402), nasopharyngeal carcinoma (KB), immature granulocyte leukemia (HL-60), and gastrocarcinoma (BGC-823) by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The results showed that most of the obtained compounds exhibited promising cytotoxicity against tested carcinoma cell lines with low IC₅₀ values. The bis-pyrazole derivative 7c, bearing alkoxy group on the 5-position of phenyl ring, was the most effective one. It is inhibition of cell growth of Bel-7402 cells was 1.5-fold higher than that found for cisplatin. And, also mono-pyrazole derivatives 5a and 5b, decorated with trifluoromethyl group on the phenyl ring, displayed better cytotoxicity than that of cisplatin against Bel-7402 cell line.     

A New Sesquiterpene Lactone from Tsoongiodendron Odorum Chun

Abstract

A new sesquiterpene lactone (1) was obtained from the cytotoxic fraction of 95% ethanol extract of root barks of Tsoongiodendron odorum Chun together with two known sesquiterpene lactones, costunolide (2) and parthenolide (3). The structure of 1 was elucidated as 5α, 6α, 7β, 10β-11α, 13-dihydro-4(15)-eudesmene-12, 6-olide on the basis of chemical and spectral evidence including X-ray diffraction analysis. Costunolide showed cytotoxic activity against human leukemia (HL-60) cell line. Parthenolide showed promising cytotoxic activities in vitro against HCT-8, Bel-7402, SKOV3, KB, HELA and EJ cell lines. Also, the cytotoxic ethyl acetate fraction of ethanol extract of the root barks from which three chemical components were isolated showed promising cytotoxic activities in vitro against KB, BGC-823, Bel-7402, HCT-8, HL-60 cell lines.     

A new sesquiterpene lactone from Tsoongiodendron odorum Chun.

A new sesquiterpene lactone (1) was obtained from the cytotoxic fraction of 95% ethanol extract of root barks of Tsoongiodendron odorum Chun together with two known sesquiterpene lactones, costunolide (2) and parthenolide (3). The structure of 1 was elucidated as 5alpha, 6alpha, 7beta, 10beta- 11alpha, 13-dihydro-4(15)-eudesmene-12, 6-olide on the basis of chemical and spectral evidence including X-ray diffraction analysis. Costunolide showed cytotoxic activity against human leukemia (HL-60) cell line. Parthenolide showed promising cytotoxic activities in vitro against HCT-8, Bel-7402, SKOV3, KB, HELA and EJ cell lines. Also, the cytotoxic ethyl acetate fraction of ethanol extract of the root barks from which three chemical components were isolated showed promising cytotoxic activities in vitro against KB, BGC-823, Bel-7402, HCT-8, HL-60 cell lines.     

New cassaine diterpenoid amides with cytotoxic activities from the bark of Erythrophleum fordii

A phytochemical investigation of the bark of Erythrophleum fordii led to six new cassaine diterpenoid amides (2, 4-8), together with two known compounds of the same skeleton, nor-cassamide ( 1) and nor-erythrosuamide (3). The structures were mainly established on the basis of 1D, 2D NMR and HR-MS analysis. The compounds 1, 2, 4, 6-8 exhibited selective cytotoxic activities (IC50 values < 10 microM) against A2780, KB, Bel-7402, BGC-823, MCF-7, HCT-8, Hela, PC-3M, A549 and Ketr3 human cancer cell lines in the MTT test.     

4-S-(5″-烃基-4″-氨基-1″,2″,4″-三唑-3″-基)-4-去氧-4′-去甲基表鬼臼毒素衍生物的合成及抗肿瘤活性

许多有显著抗肿瘤活性的鬼臼毒素类化合物,其母核C-4侧链上往往连接有刚性较强的脂环或芳香环结构,而且侧链多含有一定数量的杂原子［1～3］。另外,三氮唑类化合物大都有广泛的生物活性,如抗菌［4～5］、抗病毒［6］、抗肿瘤［7］等,据此,我们设计并合成了8个三氮唑杂环取代的表鬼臼毒素衍生物,以期寻找活性高、毒副作用小的鬼臼毒素类药物,并进一步考察此类化合物的构效关系。　合成路线如图1所示,三氮唑3a～3h和4′-去甲基-表鬼臼毒2分别按文献［8,9］方法合成;我们选择三氟乙酸作为缩合剂,基于它不仅能催化缩合反应,而且能保护三唑上的氨基官能团,使其不能充当进攻基团;最后一步缩合反应显然经历了一个SN1历程,4′-去甲基-表鬼臼毒 的C-4位上很容易形成一个苄基型碳正离子,由于C-1位有庞大的芳环,加之,进攻的基团也较大,可以预料,这个反应有很强的立体选择性,使C-4β-构型成为主要产物,事实确实如此,在TLC上几乎看不到C-4α-构型的产物。     

Synthesis,cytotoxicity, and DNA-binding property of berberine derivatives

9-Substituted berberine derivatives (4a–4f) with polyethylene glycol side chain and terminal group were synthesized and characterized by elemental (C, H, and N) and spectral analysis (NMR, HRMS and FTIR). These compounds were tested for their in vitro cytotoxic activity against four human tumor cell lines: granulocyte leukemia (HL-60), gastrocarcinoma (BGC-823), carcinoma (Bel-7402), and nasopharyngeal carcinoma (KB) by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The DNA-binding properties were investigated by UV–Vis absorption, fluorescence, CD spectroscopies, and thermal denaturation measurements. The results indicated that 4a–4f exerted cytotoxic effects with selectivity against tested cell lines. 4a exhibited higher cytotoxicity than cisplatin, berberine, and berberrubine against HL-60 and BGC-823 cell lines. The length of side chains and nature of terminal groups played an important role in the cytotoxicity. Berberine derivatives binded to CT-DNA in an intercalating mode. The binding affinities decreased with the increasing length of side chains. Compounds 4a–4c and 4e could change the DNA conformation from B to A-like form.     

Synthesis and cytotoxic activity of two steroids: icogenin aglycone analogs

During the process of icogenin analog research, we obtained two cytotoxic steroids: compound 4 and compound 6 casually. Their in vitro antitumor activities were tested by the standard MTT assay. The results disclosed that compound 4 (IC₅₀ = 3.65–6.90 μM) showed potential antitumor activities against HELA, KB cell lines and compound 6 (IC₅₀ = 2.40–9.05 μM) showed potential antitumor activities against HELA, BGC-823, KB, A549, HCT-8 cell lines.     

新型三环肟醚衍生物的合成及其抗肿瘤活性

目的设计合成8H-噻吩并[2,3-b]吡咯里嗪-8-肟醚类化合物,并对其体外抗肿瘤活性进行初步评价。方法以芳基乙腈为原料,经多步反应合成目标化合物;采用MTT法,以顺铂为阳性对照药,以Bel-7402和HT-1080为测试细胞株对目标化合物的抗肿瘤活性进行了评价。结果与结论合成了12个新化合物,经1H-NMR、MS和IR确认其结构。体外活性实验表明:化合物7d显示出较好的抗肿瘤活性。